Kirsten B Goldberg

31PUBLICATIONS
99CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (31)

|Aug 27, 2025
FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.

Melanie Royce, Mirat Shah, Lijun Zhang

|May 19, 2025
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.

Mirat Shah, Ting-Yu Chen, Gwynn Ison

|Dec 12, 2023
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development.

Joshua M Donaldson, Marjilla Seddiq, Michael J Fusco

|Apr 03, 2023
FDA Oncology Center of Excellence Crowdsourcing Initiative: Outreach to the Scientific Community to Identify Research Questions for Pooled Analyses of Oncology Clinical Trial Data.

Julie A Schneider, Julia Eckstein, Kirsten B Goldberg

|Mar 23, 2023
FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC.

Luckson N Mathieu, Erin Larkins, Arup K Sinha

|Dec 02, 2022
Highlights of FDA Oncology Approvals in 2022: Tissue-Agnostic Indications, Dosage Optimization, and Diversity in Drug Development.

Elizabeth S Duke, Michael J Fusco, Patrick DeMoss

Pageof 6

Frequent Collaborators

8 joint publications

Richard Pazdur

5 joint publications

Lola Fashoyin-Aje

3 joint publications

Paul Kluetz

3 joint publications

Marc R Theoret